Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Thomas Olin(Kancera (Sweden)), Amineh Ghaderi(Karolinska University Hospital), AmirHossein Daneshmanesh(Karolinska Institutet), Ali Moshfegh(Karolinska University Hospital), Ηλίας Δράκος(University of Crete), Parviz Kokhaei(Arak University of Medical Sciences), Jemina Lehto(Kancera (Sweden)), Charlotta Löfberg(Kancera (Sweden)), Anders Österborg(Karolinska University Hospital), Charlotta Carina Norström(Kancera (Sweden)), Jan Vågberg(Kancera (Sweden)), Elisabeth Olsson(Karolinska Institutet), Johan Schultz(Kancera (Sweden)), Martin Norin(Kancera (Sweden)), George Z. Rassidakis(Karolinska University Hospital)
Cited by 6
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
|Journal of Clinical Oncology|1998|258
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202